Wells Fargo
ZBIO

Wells Fargo’s Zenas BioPharma ZBIO Stock Holding History

Wells Fargo’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$174K Sell
8,885
-12,266
-58% -$275K ﹤0.01% 4783
2025
Q4 		$768K Buy
21,151
+8,696
+70% +$286K ﹤0.01% 4166
2025
Q3 		$277K Buy
12,455
+2,031
+19% +$33.1K ﹤0.01% 4730
2025
Q2 		$101K Buy
10,424
+2,261
+28% +$22K ﹤0.01% 5189
2025
Q1 		$64.5K Buy
8,163
+181
+2% +$1.42K ﹤0.01% 5313
2024
Q4 		$65.4K Buy
+7,982
New +$125K ﹤0.01% 5399

Other funds holding ZBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $176M AUM 208.78% 1-Year Est. Return

Wells Fargo's ZBIO Position: Q1 2026 in Review

Wells Fargo reduced its Zenas BioPharma (ZBIO) stake by 58% in Q1 2026, selling an estimated $275K and leaving 8,885 shares worth $174K. The position accounts for ﹤0.01% of the portfolio, ranked #4783.

Wells Fargo first reported a position in ZBIO in Q4 2024 and has held it in 6 quarters since. The position peaked at $768K in Q4 2025. 139 funds tracked by Wall St. Rank hold ZBIO as of Q1 2026.

  • Wells Fargo held 8,885 shares of Zenas BioPharma worth $174K as of Q1 2026.
  • Wells Fargo sold 12,266 Zenas BioPharma shares in Q1 2026, an estimated $275K.
  • Zenas BioPharma made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #4783 holding.
  • Wells Fargo first reported a position in Zenas BioPharma in Q4 2024 and has held it in 6 quarters since.
  • Wells Fargo's Zenas BioPharma position peaked at $768K in Q4 2025.
  • 139 funds tracked by Wall St. Rank held Zenas BioPharma as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.